Literature DB >> 14965777

Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus.

Haifang Sun1, Haibin Luo, Changying Yu, Tao Sun, Jing Chen, Shuying Peng, Jun Qin, Jianhua Shen, Yiming Yang, Youhua Xie, Kaixian Chen, Yuan Wang, Xu Shen, Hualiang Jiang.   

Abstract

Severe acute respiratory syndrome (SARS) is an acute respiratory illness, which has broken out in China. It has been known that SARS coronavirus (SARS_CoV) is a novel human coronavirus and is responsible for SARS infection. Belonging to one of the major proteins associated with SARS_CoV, SARS 3C-like protease (SARS_3CL(pro)) functions as a cysteine protease engaging in the proteolytic cleavage of the viral precursor polyprotein to a series of functional proteins required for coronavirus replication and is considered as an appealing target for designing anti-SARS agents. To facilitate the studies regarding the functions and structures of SARS_3CL(pro), in this report the synthetic genes encoding 3CL(pro) of SARS_CoV were assembled, and the plasmid was constructed using pQE30 as vector and expressed in Escherichia coli M15 cells. The highly yielded ( approximately 15mg/L) expressed protease was purified by use of NTA-Ni(2+) affinity chromatography and FPLC system, and its sequence was determined by LC/MS with the residue coverage of 46.4%.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14965777     DOI: 10.1016/j.pep.2003.08.016

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  17 in total

1.  Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.

Authors:  Jon Jacobs; Valerie Grum-Tokars; Ya Zhou; Mark Turlington; S Adrian Saldanha; Peter Chase; Aimee Eggler; Eric S Dawson; Yahira M Baez-Santos; Sakshi Tomar; Anna M Mielech; Susan C Baker; Craig W Lindsley; Peter Hodder; Andrew Mesecar; Shaun R Stauffer
Journal:  J Med Chem       Date:  2013-01-03       Impact factor: 7.446

2.  Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Authors:  Lili Chen; Chunshan Gui; Xiaomin Luo; Qingang Yang; Stephan Günther; Elke Scandella; Christian Drosten; Donglu Bai; Xichang He; Burkhard Ludewig; Jing Chen; Haibin Luo; Yiming Yang; Yifu Yang; Jianping Zou; Volker Thiel; Kaixian Chen; Jianhua Shen; Xu Shen; Hualiang Jiang
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Down-regulation of granulocyte-macrophage colony-stimulating factor by 3C-like proteinase in transfected A549 human lung carcinoma cells.

Authors:  Hsien-Hua Liao; Yao-Chen Wang; Miles Chih-Ming Chen; Hsien-Yu Tsai; Johnson Lin; Shui-Tein Chen; Gregory Jiazer Tsay; Sun-Long Cheng
Journal:  BMC Immunol       Date:  2011-02-17       Impact factor: 3.615

4.  Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.

Authors:  Valerie Grum-Tokars; Kiira Ratia; Adrian Begaye; Susan C Baker; Andrew D Mesecar
Journal:  Virus Res       Date:  2007-03-29       Impact factor: 3.303

5.  Microarray and real-time RT-PCR analyses of differential human gene expression patterns induced by severe acute respiratory syndrome (SARS) coronavirus infection of Vero cells.

Authors:  W F Leong; H C Tan; E E Ooi; D R Koh; Vincent T K Chow
Journal:  Microbes Infect       Date:  2005-01-22       Impact factor: 2.700

6.  Study on substrate specificity at subsites for severe acute respiratory syndrome coronavirus 3CL protease.

Authors:  Yu-Fei Shan; Gen-Jun Xu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2005-12       Impact factor: 3.848

7.  Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay.

Authors:  Richard Y Kao; Amanda P C To; Louisa W Y Ng; Wayne H W Tsui; Terri S W Lee; Hoi-Wah Tsoi; Kwok-Yung Yuen
Journal:  FEBS Lett       Date:  2004-10-22       Impact factor: 4.124

8.  Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.

Authors:  Ji-Young Park; Jang Hoon Kim; Young Min Kim; Hyung Jae Jeong; Dae Wook Kim; Ki Hun Park; Hyung-Jun Kwon; Su-Jin Park; Woo Song Lee; Young Bae Ryu
Journal:  Bioorg Med Chem       Date:  2012-08-02       Impact factor: 3.641

9.  Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure.

Authors:  Tiancen Hu; Yu Zhang; Lianwei Li; Kuifeng Wang; Shuai Chen; Jing Chen; Jianping Ding; Hualiang Jiang; Xu Shen
Journal:  Virology       Date:  2009-05-05       Impact factor: 3.616

10.  Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.

Authors:  Ji-Young Park; Jang Hoon Kim; Jung Min Kwon; Hyung-Jun Kwon; Hyung Jae Jeong; Young Min Kim; Doman Kim; Woo Song Lee; Young Bae Ryu
Journal:  Bioorg Med Chem       Date:  2013-04-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.